Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 22:20:100174.
doi: 10.1016/j.jctube.2020.100174. eCollection 2020 Aug.

Clinical efficacy of vitamin D supplementation on pulmonary TB patients: The evidence of clinical trials

Mohsen Karbalaei  1 , Kiarash Ghazvini  2   3 , Masoud Keikha  2   3   4
Affiliations

Clinical efficacy of vitamin D supplementation on pulmonary TB patients: The evidence of clinical trials

Mohsen Karbalaei et al. J Clin Tuberc Other Mycobact Dis. .

Erratum in

  • Erratum regarding previously published articles.
    [No authors listed] [No authors listed] J Clin Tuberc Other Mycobact Dis. 2021 May 6;24:100242. doi: 10.1016/j.jctube.2021.100242. eCollection 2021 Aug. J Clin Tuberc Other Mycobact Dis. 2021. PMID: 34095548 Free PMC article.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The crucial role of vitamin D in the immunopathogenesis of TB. Vitamin D has immunomodulatory effects on the immune-system, so that it suppresses Th1, Th17, B cell as well as DCs maturation. However, it also stimulates the proliferation of T regulatory (T reg) cells, which in turn inhibit the excessive T cell-mediated immunity and tissue damage. In the other hand, it also has a specific receptor on the macrophages, vitamin D receptor (VDR). After the binding to the VDR, vitamin D triggers the processes such as the production of natural human antimicrobial peptides (AMPs), nitric oxide synthesis and chemotaxis to provoke immune response for clearance of M. tuberculosis (Mtb).
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis report 2019. World Health Organization; 2020.
    1. Keikha M., Eslami M., Yousefi B., Karbalaei M. Overview of multistage subunit tuberculosis vaccines: advantages and challenges. Rev Med Microbiol. 2020
    1. Keikha M. There is significant relationship between Beijing genotype family strains and resistance to the first-line anti-tuberculosis drugs in the Iranian population. J Clin Tuberculosis Other Mycobacterial Diseases. 2020;19 - PMC - PubMed
    1. Najafi A., Mahdian N., Yousefi B., Karbalaei M., Ezatpour B., Eslami M. New vaccine candidates as a scientific solution against the dream of tuberculosis vaccine. Rev Med Microbiol. 2020;31(3):126–134.
    1. Dheda K., Gumbo T., Maartens G., Dooley K.E., McNerney R., Murray M. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291–360. - PubMed

LinkOut - more resources